TABLE 4.
Multivariate Models With Significant Risk Factors
| Risk Factor | Unadjusted HR (95% CI) | P | Adjusted HR (95% CI) | P |
|---|---|---|---|---|
| Overall survival | ||||
| Additional neuroimaging follow-up | 0.655 (0.583-0.737) | <.001 | 0.653 (0.578-0.739) | <.001 |
| GPA | 0.657 (0.481 -0.896) | .008 | 0.656 (0.460-0.935) | .02 |
| Additional day from consultation to SRS | 1.003 (0.994-1.011) | .52 | 0.999 (0.989, 1.009) | .83 |
| Tumor histology | ||||
| Lung adenocarcinoma | Reference | Reference | Reference | Reference |
| Breast adenocarcinoma | 1.261 (0.599-2.652) | .54 | 2.199 (1.023-4.726) | .04 |
| Melanoma | 1.526 (0.725-3.211) | .27 | 2.912 (1.363-6.224) | .006 |
| Renal cell carcinoma | 1.256 (0.597-2.644) | .55 | 1.545 (0.730-3.273) | .26 |
| Other | 1.623 (0.887-2.972) | .12 | 1.496 (0.808-2.773) | .20 |
| Salvage neurosurgery | ||||
| Safety-net hospital | 3.293 (1.194-9.082) | .02 | 13.65 (3.311-56.29) | <.001 |
| Neurologic symptoms at baseline | 3.313 (1.218-9.012) | .02 | 11.40 (2.819-46.12) | <.001 |
| Additional brain metastasis | 1.155 (1.002-1.332) | .05 | 1.260 (1.074-1.478) | .005 |
| Additional day from consultation to SRS | 1.001 (0.980,1.022) | .96 | 0.994 (0.955-1.036) | .79 |
| Tumor histology | ||||
| Lung adenocarcinoma | Reference | Reference | Reference | Reference |
| Breast adenocarcinoma | 1.023 (0.092-11.29) | .99 | 0.493 (0.039-6.207) | .58 |
| Melanoma | 7.082 (1.368-36.68) | .02 | 22.73 (3.244-159.29) | .002 |
| Renal cell carcinoma | 3.402 (0.567-20.41) | .18 | 5.763 (0.907-36.64) | .06 |
| Other | 3.537 (0.679-18.41) | .13 | 4.250 (0.790-22.87) | .09 |
| Any neurologic symptoms | ||||
| Safety-net hospital | 2.644 (1.352-5.172) | .004 | 3.739 (1.599-8.743) | .002 |
| Early stage (I/II) at diagnosis | 0.377 (0.183-0.774) | .008 | 0.280 (0.120-0.656) | .003 |
| Additional neuroimaging follow-up | 0.859 (0.759-0.972) | .02 | 0.865 (0.766-0.977) | .02 |
| Additional day from consultation to SRS | 0.997 (0.980-1.014) | .70 | 0.979 (0.957-1.002) | .08 |
| Tumor histology | ||||
| Lung adenocarcinoma | Reference | Reference | Reference | Reference |
| Breast adenocarcinoma | 3.103 (1.120-8.598) | .03 | 3.702 (1.303-10.52) | .01 |
| Melanoma | 2.162 (0.724-6.456) | .17 | 2.851 (0.915-8.877) | .07 |
| Renal cell carcinoma | 1.412 (0.446-4.468) | .56 | 2.301 (0.720-7.360) | .16 |
| Other | 1.922 (0.712-5.190) | .20 | 1.470 (0.532-4.061) | .46 |
| Hospitalization for brain metastases | ||||
| Safety-net hospital | 4.371 (1.693-11.29) | .002 | 6.248 (2.222-17.57) | <.001 |
| Additional clinical follow-up | 0.786 (0.659-0.937) | .007 | 0.749 (0.622-0.902) | .002 |
| Additional brain metastasis | 1.216 (1.003-1.474) | .46 | 1.316 (1.052-1.647) | .02 |
| Additional day from consultation to SRS | 1.000 (0.984-1.017) | .971 | 0.988 (0.958-1.018) | .42 |
| Tumor histology | ||||
| Lung adenocarcinoma | Reference | Reference | Reference | Reference |
| Breast adenocarcinoma | 1.183 (0.283-4.959) | .82 | 2.585 (0.576-11.60) | .22 |
| Melanoma | 2.592 (0.689-9.746) | .16 | 3.360 (0.875-12.90) | .08 |
| Renal cell carcinoma | 2.948 (0.777-11.18) | .11 | 4.584 (1.122-18.72) | .03 |
| Other | 1.570 (0.450-5.471) | .48 | 2.831 (0.727-11.02) | .13 |
Abbreviations: CI, confidence interval; GPA, graded prognostic assessment; HR, hazard ratio; SRS, stereotactic radiosurgery.